Advertisement

Management of chronic ischemic heart disease into internal medicine and geriatric departments in Italy

  • Francesco PerticoneEmail author
  • Andrea Fontanella
  • Nicola Ferrara
  • Alberto Ferrari
Research Letter to the editor

Dear Editor,

Chronic ischemic heart disease (IHD), represented by stable angina pectoris, is currently a major clinical and social problem; its estimated prevalence in Europe is of about 30,000–40,000 people per million inhabitants. However, published data often underestimate the real prevalence of the disease, because they do not take into account asymptomatic IHD, patients who have clinical manifestations of ischemia in the absence of diagnosed IHD, or patients who have a known coronary disease but clinical manifestations different from angina, such as congestive heart failure [1].

The prevalence of chronic IHD is progressively increasing for the following reasons: (a) the aging of population; (b) the reduction in mortality during acute coronary syndrome, with consequent increase of progression to stability; (c) the increase of some risk factors such as obesity and diabetes [2].

Even if stable angina is the most frequent clinical manifestation of chronic IHD, many patients may not...

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Statement of human and animal rights

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

For this type of study, formal consent is not required.

References

  1. 1.
    National Institutes of Health NH, Lung, and Blood Institute. Morbidity and mortality: 2012 chart book on cardiovascular, lung, and blood diseases. Bethesda, MD: National Heart, Lung, and Blood Institute: 2012.Google Scholar
  2. 2.
    Daly CA, De Stavola B, Sendon JL et al (2006) Predicting prognosis in stable angina: results from the Euro heart survey of stable angina: prospective observational study. BMJ 332:262–267CrossRefGoogle Scholar
  3. 3.
    Arnold SV, Jang JS, Tang F et al (2015) Prediction of residual angina after percutaneous coronary intervention. Eur Heart J 1:23–30Google Scholar
  4. 4.
    Perk J, De Backer G, Gohlke H et al (2012) European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice Developed with the special contribution of the European Association for Cardiovascular Prevention and Rehabilitation (EACPR). Eur Heart J 33:1635–1701CrossRefGoogle Scholar
  5. 5.
    Commissione ANMCO/GICR-IACPR/GISE, Greco C, Bovenzi FM, Berti S et al (2014) Documento ANMCO/GICR-IACPR/GISE—L’organizzazione dell’assistenza nella fase post-acuta delle sindromi coronariche. G Ital Cardiol 15(Suppl 1):3S–27SGoogle Scholar
  6. 6.
    Cannon CP, Harrington RA, James S et al (2010) Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndrome (PLATO): a ranomised double-blind study. Lancet 375:283–293CrossRefGoogle Scholar
  7. 7.
    Yusuf S, Wittes J, Friedman L (1988) Overview of results of randomized clinical trials in heart disease. Treatments following myocardial infarction. JAMA 260:2088–2093CrossRefGoogle Scholar
  8. 8.
    Jerling M (2006) Clinical pharmacokinetics of ranolazine. Clin Pharmacokinet 45:469–491CrossRefGoogle Scholar
  9. 9.
    Timmis AD, Chaitman BR, Crager M (2006) Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes. Eur Heart J 27:42–48CrossRefGoogle Scholar
  10. 10.
    Morrow DA, Scirica BM, Chaitman BR et al (2009) Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial. Circulation 119:2032–2039CrossRefGoogle Scholar
  11. 11.
    Rayner-Hartley E, Parvand M, Humphries KH et al (2018) Ranolazine for symptomatic management of microvascular angina. Am J Ther.  https://doi.org/10.1097/MJT.0000000000000779 CrossRefPubMedGoogle Scholar
  12. 12.
    Safdar B, D’Onofrio G, Dziura J et al (2017) Ranolazine and microvascular angina by PET in the Emergency Department: results from a pilot randomized controlled trial. Clin Ther 39:55–63CrossRefGoogle Scholar
  13. 13.
    Califf RM, Mark DB, Harrell FE Jr et al (1988) Importance of clinical measures of ischemia in the prognosis of patients with documented coronary artery disease. J Am Coll Cardiol 11:20–26CrossRefGoogle Scholar

Copyright information

© Società Italiana di Medicina Interna (SIMI) 2019

Authors and Affiliations

  • Francesco Perticone
    • 1
    Email author
  • Andrea Fontanella
    • 2
  • Nicola Ferrara
    • 3
  • Alberto Ferrari
    • 4
  1. 1.Italian Society of Internal Medicine (SIMI)RomeItaly
  2. 2.Federazione Delle Associazioni dei Dirigenti Ospedalieri Internisti (FADOI)RomeItaly
  3. 3.Società Italiana di Geriatria e Gerontologia (SIGG)FlorenceItaly
  4. 4.Società Italiana dei Geriatri Ospedalieri e del Territorio (SIGOT)RomeItaly

Personalised recommendations